Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEON NASDAQ:ANEB NASDAQ:GELS NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.76+0.3%$0.93$0.53▼$1.45$19.21M0.66131,280 shs34,284 shsANEBAnebulo Pharmaceuticals$0.47$0.60$0.30▼$3.42$19.17M-1.9348,670 shs3,820 shsGELSGelteq$0.49$0.61$0.39▼$3.51$5.24M-0.19192,915 shs60,107 shsQNCXQuince Therapeutics$1.15$1.18$0.79▼$45.50$18.75M1.42.05 million shs699,644 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%-2.34%-17.05%-28.40%+31.77%ANEBAnebulo Pharmaceuticals0.00%+2.17%+6.82%+8.22%-53.00%GELSGelteq0.00%+15.88%-24.19%-36.83%-68.65%QNCXQuince Therapeutics0.00%+4.55%-12.21%+16.40%-88.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEONAEON Biopharma$0.76+0.3%$0.93$0.53▼$1.45$19.21M0.66131,280 shs34,284 shsANEBAnebulo Pharmaceuticals$0.47$0.60$0.30▼$3.42$19.17M-1.9348,670 shs3,820 shsGELSGelteq$0.49$0.61$0.39▼$3.51$5.24M-0.19192,915 shs60,107 shsQNCXQuince Therapeutics$1.15$1.18$0.79▼$45.50$18.75M1.42.05 million shs699,644 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEONAEON Biopharma0.00%-2.34%-17.05%-28.40%+31.77%ANEBAnebulo Pharmaceuticals0.00%+2.17%+6.82%+8.22%-53.00%GELSGelteq0.00%+15.88%-24.19%-36.83%-68.65%QNCXQuince Therapeutics0.00%+4.55%-12.21%+16.40%-88.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEONAEON Biopharma 3.00BuyN/AN/AANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/AGELSGelteq 1.00SellN/AN/AQNCXQuince Therapeutics 1.71Reduce$65.005,552.17% UpsideCurrent Analyst Ratings BreakdownLatest GELS, ANEB, AEON, and QNCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026AEONAEON Biopharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/7/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026QNCXQuince Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEONAEON BiopharmaN/AN/AN/AN/A($4.12) per shareN/AANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/AGELSGelteq$110K47.61N/AN/A$1.08 per share0.45QNCXQuince TherapeuticsN/AN/AN/AN/A($6.41) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEONAEON Biopharma-$36.63M-$5.004.22N/AN/AN/AN/A-994.63%8/11/2026 (Estimated)ANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%N/AGELSGelteq-$4.30MN/AN/AN/AN/AN/AN/AN/AN/AQNCXQuince Therapeutics-$83.98M-$10.62N/AN/AN/AN/A-372.88%-67.99%8/11/2026 (Estimated)Latest GELS, ANEB, AEON, and QNCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026QNCXQuince Therapeutics-$1.30-$0.59+$0.71$2.88N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEONAEON BiopharmaN/AN/AN/AN/AN/AANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEONAEON BiopharmaN/A0.220.22ANEBAnebulo PharmaceuticalsN/A6.246.24GELSGelteqN/AN/AN/AQNCXQuince TherapeuticsN/A2.922.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEONAEON Biopharma22.78%ANEBAnebulo Pharmaceuticals28.40%GELSGelteqN/AQNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipAEONAEON Biopharma9.40%ANEBAnebulo Pharmaceuticals80.60%GELSGelteqN/AQNCXQuince Therapeutics7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEONAEON Biopharma525.30 million74.37 millionNot OptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableGELSGelteqN/A10.71 millionN/AN/AQNCXQuince Therapeutics6016.30 million15.14 millionOptionableGELS, ANEB, AEON, and QNCX HeadlinesRecent News About These CompaniesQuince Therapeutics Regains Nasdaq Compliance, Avoids Delisting RiskMay 24, 2026 | theglobeandmail.comQuince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks TranscriptMay 18, 2026 | seekingalpha.comUPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDMay 18, 2026 | globenewswire.comQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDMay 18, 2026 | globenewswire.comQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary PipelineMay 18, 2026 | globenewswire.comQuince Therapeutics (QNCX) price target increased by 100.00% to 81.60May 15, 2026 | msn.comQuince Therapeutics (QNCX) price target increased by 900.00% to 40.80April 28, 2026 | msn.comQuince Therapeutics Delays Annual 10-K FilingApril 27, 2026 | theglobeandmail.comQuince Therapeutics settles $16.4M debt with $5.5M paymentMarch 30, 2026 | msn.comWhy did QNCX stock surge 40% in pre-market today?March 30, 2026 | msn.comQuince Therapeutics Settles Approximately $16.4 Million of DebtMarch 30, 2026 | businesswire.comBankruptcy threat looms as Quince runs out of optionsFebruary 13, 2026 | pharmaphorum.comPQuince Therapeutics stock plummets after revealing strategic alternativesFebruary 13, 2026 | au.investing.comQuince Therapeutics (QNCX) Stock Erupts 300% as Buyout Rumors EmergeFebruary 11, 2026 | blockonomi.comQuince Therapeutics stock soars after engaging LifeSci Capital as advisorFebruary 10, 2026 | au.investing.comWhy is QNCX stock up 60% pre-market after a near-total wipeout?February 10, 2026 | msn.comQuince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic AlternativesFebruary 9, 2026 | businesswire.comPolaryx Therapeutics, Inc. Strengthens Board of Directors with New Appointments as Company Advances to Phase 2 TrialFebruary 5, 2026 | quiverquant.comQQuince Therapeutics Announces Significant Board of Directors ResignationsFebruary 4, 2026 | theglobeandmail.comQuince Therapeutics (QNCX) price target decreased by 21.74% to 6.12February 4, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGELS, ANEB, AEON, and QNCX Company DescriptionsAEON Biopharma NASDAQ:AEON$0.76 +0.00 (+0.30%) Closing price 05/29/2026 03:55 PM EasternExtended Trading$0.74 -0.02 (-2.77%) As of 06:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.Anebulo Pharmaceuticals NASDAQ:ANEB$0.47 0.00 (0.00%) As of 05/29/2026 02:44 PM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Gelteq NASDAQ:GELS$0.49 0.00 (0.00%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$0.47 -0.02 (-3.27%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Quince Therapeutics NASDAQ:QNCX$1.15 0.00 (0.00%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.17 +0.02 (+1.74%) As of 06:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
